The private versus public contribution to the biomedical literature during the COVID-19, Ebola, H1N1, and Zika public health emergencies.
<h4>Background</h4>The private versus public contribution to developing new health knowledge and interventions is deeply contentious. Proponents of commercial innovation highlight its role in late-stage clinical trials, regulatory approval, and widespread distribution. Proponents of publ...
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Public Library of Science (PLoS)
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/e45fe741b7bf4d2284cc8e2b27d3bdc8 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|